AMLX(Amylyx Pharmaceuticals, Inc.) · 财务报表

AMLX(Amylyx Pharmaceuticals, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$285.00K$22.23M$380.79M$87.37M$0
毛利润—$19.24M$355.35M$81.42M$0
营业利润−$82.69M−$201.34M$38.80M−$314.73M−$153.29M
净利润−$87.93M−$198.38M$49.27M−$301.74M−$144.74M
经营现金流−$74.80M−$179.87M$11.92M−$167.65M−$123.34M
自由现金流−$75.15M−$182.40M$10.68M−$167.80M−$123.48M
摊薄每股收益$-13.35$-3.39$0.70$-4.43$-1.53

Amylyx Pharmaceuticals, Inc. AMLX